NovoCure reported Q1 2026 net revenues of $174.1 million, up 12% year-over-year, with gross margin expansion to 78% and updated full-year revenue guidance to $690-$710 million.
Key takeaways
Q1 2026 net revenues $174.1 million, +12% YoY, driven by active patient growth in Europe.
Gross margin improved to 78% from 75% due to lower array costs.
GAAP net loss $71.1 million, EPS $(0.62); Adjusted EBITDA $(0.3) million.
Total active patients 4,791, up 12% YoY, including 83 on new Optune Pax.